-
-
-
-
-
-
-
Tevogen Bio posts 51% reduction in nine-month operating loss
-
-
-
-
-
-
-
Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
-
-
-
-
-
-
-
Tevogen reports 60% rise in institutional stock ownership
-
-
-
-
-
-
-
Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
-
-
-
-
-
-
-
Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcellâ„¢ Alpha Launch
-
-
-
-
-
-
-
Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow
-
-
-
-
-
-
-
Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

